Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial

2021/10/28 by Selina M. Luger, Victoria X. Wang, Jacob M. Rowe +19
Biochemistry, Genetics and Molecular Biology · Medicine · #Acute Myeloid Leukemia Research #Chronic Myeloid Leukemia Treatments #Retinoids in leukemia and cellular processes

paper · doi:10.1016/j.leukres.2021.106736

openalex publication_date 2021/10/28 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29

Citations

• Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432
• Nonparametric Estimation from Incomplete Observations